Fecal blood loss caused by two differently microencapsulated acetylsalicylic acid preparations in patients with rheumatoid arthritis. A prospective crossover study.
In an investigator-blind crossover study, fecal blood loss determined by 51Cr-labelled red cells was measured in 17 male patients with rheumatoid arthritis and one with anchylosing spondylitis. In two periods, each of one week's duration and separated by a 3-week wash-out period, the patients received microencapsulated acetylsalicylic acid (ASA) 3 g daily--either iwht time-dependent (Acetard) or with pH-depeendent release (Reumyl). With the exception of one patient, who suffered clinically significant bleeding, both preparations produced only moderate bleeding. The bleeding provoked by ASA with pH-dependent release (median blood loss in ml/day: first period 1.6; last period 2.6) was less than with time-dependent release (first period 1.8; last period 3.5).
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001241:Aspirin / Q000009:adverse effects* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects; D008277:Magnesium Oxide / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008551:Melena / Q000139:chemically induced*; D008875:Middle Aged; D013167:Spondylitis, Ankylosing / Q000188:drug therapy
D003692:Delayed-Action Preparations; D004338:Drug Combinations; D008277:Magnesium Oxide; C024079:aspirin, magnesium oxide combination; D001241:Aspirin